康弘药业：目前中成药板块的KH110（治疗阿尔茨海默症）处于临床III期阶段

Core Viewpoint - The company is currently in the clinical III phase for its traditional Chinese medicine product KH110, aimed at treating Alzheimer's disease, amidst increasing concerns about the rising prevalence of Alzheimer's and depression in China [2] Company Research - KH110, the company's drug for Alzheimer's disease, is in the clinical III phase [2] - The company has acknowledged the growing population of Alzheimer's patients and the decreasing age of onset [2] - There is an indication of increased investment in research and development related to depression, reflecting the rising number of depression cases in the country [2]